Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients with post-COVID syndrome.
The University Hospital of Erlangen recently completed a phase 2a investigator-initiated trial (reCOVer) of rovunaptabin in 30 patients with post-COVID syndrome (EudraCT 2022-001781-35). The study confirmed the safety and tolerability of rovunaptabin, with improvements in fatigue and post-exertional malaise (PEM) observed. Furthermore, MRIs and functional imaging revealed that resting brain activity normalised during rovunaptabin therapy, […]
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID (BLOC)
Rovunaptabin was recently evaluated in a randomised, placebo-controlled phase 2 clinical study (BLOC), conducted at 15 sites across five EU countries (NCT05911009). The study enrolled 114 patients with Long COVID and compared the efficacy of two dosage levels of rovunaptabin against placebo control. The study confirmed that rovunaptabin was safe and well tolerated. However, the […]
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor.
In a recently completed randomised phase 2a clinical trial involving 30 subjects with heart failure (NCT04192214), treatment with rovunaptabin was found to be safe and well tolerated. Furthermore, the study showed promising improvements in cardiac performance, as measured by left ventricular ejection fraction (LVEF), in patients who received the treatment.Further clinical investigator-initiated trials are planned […]